Membrane transporters in drug development and as determinants of precision medicine
A Galetin, KLR Brouwer, D Tweedie… - Nature Reviews Drug …, 2024 - nature.com
The effect of membrane transporters on drug disposition, efficacy and safety is now well
recognized. Since the initial publication from the International Transporter Consortium …
recognized. Since the initial publication from the International Transporter Consortium …
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation
AT Nies, E Schaeffeler, M Schwab - Pharmacology & Therapeutics, 2022 - Elsevier
Organic cation transporters (OCT), organic anion transporting polypeptides (OATP) and
organic anion transporters (OAT) from the solute carrier (SLC) family play an essential role …
organic anion transporters (OAT) from the solute carrier (SLC) family play an essential role …
Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs
J Lin, E Kimoto, S Yamazaki… - Clinical …, 2023 - Wiley Online Library
Hepatic impairment (HI) is known to modulate drug disposition and may lead to elevated
plasma exposure. The aim of this study was to quantitate the in vivo OATP1B‐mediated …
plasma exposure. The aim of this study was to quantitate the in vivo OATP1B‐mediated …
Physiologically‐based pharmacokinetic modeling‐guided dose Management of Oral Anticoagulants when initiating Nirmatrelvir/ritonavir (Paxlovid) for COVID‐19 …
Patients with coronavirus disease 2019 (COVID‐19) with cardiovascular diseases who are
at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir …
at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir …
Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling
J Dong, L Prieto Garcia, Y Huang… - Clinical …, 2023 - Wiley Online Library
A different drug–drug interaction (DDI) scenario may exist in patients with chronic kidney
disease (CKD) compared with healthy volunteers (HVs), depending on the interplay …
disease (CKD) compared with healthy volunteers (HVs), depending on the interplay …
Using Endogenous Biomarkers to Derisk Assessment of Transporter‐Mediated Drug‐Drug Interactions: A Scientific Perspective
V Arya, KS Reynolds, X Yang - The Journal of Clinical …, 2022 - Wiley Online Library
Comprehensive characterization of transporter mediated drug‐drug interactions (DDIs) is
important to formulate clinical management strategies and ensure the safe and effective use …
important to formulate clinical management strategies and ensure the safe and effective use …
Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease
SPF Tan, ME Willemin, J Snoeys… - Clinical …, 2023 - Wiley Online Library
Monitoring endogenous biomarkers is increasingly used to evaluate transporter‐mediated
drug–drug interactions (DDIs) in early drug development and may be applied to elucidate …
drug–drug interactions (DDIs) in early drug development and may be applied to elucidate …
Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry
R Kikuchi, PP Chothe, X Chu, F Huth… - Clinical …, 2023 - Wiley Online Library
Drug–drug interactions (DDIs) involving hepatic organic anion transporting polypeptides
1B1/1B3 (OATP1B) can be substantial, however, challenges remain for predicting …
1B1/1B3 (OATP1B) can be substantial, however, challenges remain for predicting …
A 20-year research overview: quantitative prediction of hepatic clearance using the in vitro-in vivo extrapolation approach based on physiologically based …
Y Sugiyama, Y Aoki - Drug Metabolism and Disposition, 2023 - ASPET
Understanding the extended clearance concept and establishing a physiologically based
pharmacokinetic (PBPK) model are crucial for investigating the impact of changes in …
pharmacokinetic (PBPK) model are crucial for investigating the impact of changes in …
Quantitative characterization of clinically relevant drug-metabolizing enzymes and transporters in rat liver and intestinal segments for applications in PBPK modeling
Rats are extensively used as a preclinical model for assessing drug pharmacokinetics (PK)
and tissue distribution; however, successful translation of the rat data requires information …
and tissue distribution; however, successful translation of the rat data requires information …